Skip to content

EyePoint, Inc. EYPT Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Merck & Co. logo
Merck & Co.MRK
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Theravance Biopharma logo
Theravance BiopharmaTBPH
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's deferred tax assets and other non-current assets?
EyePoint, Inc. (EYPT) reported deferred tax assets and other non-current assets of $9.3M in Q1 2026.
How has EyePoint, Inc. 's deferred tax assets and other non-current assets changed year-over-year?
EyePoint, Inc. 's deferred tax assets and other non-current assets increased by 58.3% year-over-year, from $5.88M to $9.3M.